NASDAQ$IART
Integra LifeSciences Holdings Corporation · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Integra LifeSciences reported better-than-expected first quarter revenue with organic growth exceeding five percent.
Integra LifeSciences reported a 4.6% increase in revenue to $376.6 million in Q1 2022. GAAP earnings per diluted share were $0.39, while adjusted earnings per diluted share were $0.74. The company raised its full-year 2022 organic growth guidance to a new range of 3.8% to 5.2%.
- Revenues of $376.6 million increased 4.6% on a reported basis and 5.6% on an organic basis compared to the prior year.
- GAAP earnings per diluted share of $0.39, compared to $0.53 in the first quarter of 2021; adjusted earnings per diluted share of $0.74, compared to $0.69 in the prior year.
- The Company is raising its previous full-year 2022 organic growth guidance of 3.5% to 5% to a new range of 3.8% to 5.2%, reflecting the better than expected first quarter revenue results.
- NeuraGen® 3D, the Company's new peripheral nerve repair product, launched late in the first quarter.
Headline financials
Revenue & EPS history
Integra LifeSciences · Revenue · Quarterly
$377M
Revenue by segment
Integra LifeSciences · $360M total across 4 segments · Q1 2021
- Neurosurgery$189M+2.3%52.6%
- Wound Reconstruction and Care$88.7M+22.7%24.6%
- Instruments$52M+11.8%14.4%
- Private Label$30.1M+3.4%8.4%
Forward guidance
For the second quarter 2022, the Company expects reported revenues in the range of $392 million to $400 million, representing reported growth of approximately 0.5% to 2.5% and organic growth of approximately 2.8% to 4.8%. Adjusted earnings per diluted share are expected to be in a range of $0.78 to $0.82. For the full year 2022, the Company is raising its organic growth expectations from an initial range of 3.5% to 5% to now 3.8% to 5.2%.
Tailwinds
- Company expects reported revenues in the range of $392 million to $400 million
- Company expects reported growth of approximately 0.5% to 2.5%
- Company expects organic growth of approximately 2.8% to 4.8%
- Adjusted earnings per diluted share are expected to be in a range of $0.78 to $0.82.
- Company is raising its organic growth expectations from an initial range of 3.5% to 5% to now 3.8% to 5.2%.
Headwinds
- Reflects current uncertainty in global markets
- Reflects continuing supply constraints
- Reflects absorbing an additional 30 basis points unfavorable currency impact
- Principally driven by the continuing strengthening of the US dollar against other currencies
- Full year 2022 adjusted earnings per diluted share guidance is unchanged and is expected to be in a range of $3.27 to $3.35.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.2%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-1.8%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+29.2%
Q3 2024
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.4% | +31.0% | +65.1% | |
| Q4 2025 | -2.1% | -8.9% | -20.6% | |
| Q3 2025 | -23.5% | -26.8% | -15.0% | |
| Q1 2025 | -20.9% | -27.3% | -22.3% | |
| Q4 2024 | +12.1% | +5.3% | -0.2% | |
| Q3 2024 | +29.2% | +28.5% | +25.1% | |
| Q2 2024 | -20.4% | -23.5% | -35.3% | |
| Q1 2024 | -13.2% | -10.0% | +9.9% | |
| Q4 2023 | -16.6% | -18.8% | -19.9% | |
| Q3 2023 | -4.5% | -5.8% | +6.3% | |
| Q2 2023 | -3.1% | -1.1% | -9.5% | |
| Q1 2023 | -6.2% | -5.5% | -34.7% | |
| Q4 2022 | +0.2% | +0.8% | -3.1% | |
| Q3 2022 | +11.1% | +12.7% | +21.1% | |
| Q2 2022 | -1.5% | -0.5% | -14.8% | |
| Q1 2022 | +2.9% | -0.2% | +2.5% | |
| Q4 2021 | +0.9% | +2.6% | -2.8% | |
| Q3 2021 | +7.1% | +7.5% | -5.3% | |
| Q2 2021 | -0.2% | -0.3% | +2.6% | |
| Q1 2021 | -2.0% | -3.4% | -9.9% | |
| Q4 2020 | -4.1% | -2.8% | -6.2% | |
| Q3 2020 | -7.0% | -4.5% | +19.5% | |
| Q2 2020 | +6.4% | +6.6% | -5.6% | |
| Q1 2020 | +1.5% | -2.8% | +7.9% | |
| Q4 2019 | +2.9% | -0.3% | -35.7% | |
| Q3 2019 | -7.7% | -5.1% | -2.0% | |
| Q2 2019 | +12.0% | +14.5% | +8.0% | |
| Q1 2019 | -3.1% | -2.3% | -7.7% | |
| Q4 2018 | +5.7% | +6.1% | +6.5% | |
| Q3 2018 | -12.6% | -13.5% | -13.9% | |
| Q2 2018 | -2.3% | -2.3% | -5.5% | |
| Q1 2018 | +9.8% | +12.7% | +16.7% | |
| Q4 2017 | -4.1% | -4.1% | +0.7% | |
| Q3 2017 | -9.1% | -8.2% | -4.9% | |
| Q2 2017 | -9.9% | -10.7% | -10.9% | |
| Q1 2017 | +4.6% | +5.1% | +12.1% | |
| Q4 2016 | -2.1% | -1.2% | -1.2% | |
| Q3 2016 | +1.6% | -3.4% | +3.8% | |
| Q2 2016 | +6.8% | +6.4% | +9.0% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | +2.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | +7.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -7.5% | — | — | |
| Q2 2014 | +1.0% | — | — | |
| Q1 2014 | -1.6% | — | — | |
| Q4 2013 | -3.9% | — | — | |
| Q3 2013 | +4.4% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | +0.2% | — | — | |
| Q4 2012 | -4.8% | — | — | |
| Q3 2012 | -0.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | +9.4% | — | — | |
| Q4 2011 | +1.2% | — | — | |
| Q3 2011 | -21.8% | — | — | |
| Q2 2011 | -5.3% | — | — | |
| Q1 2010 | +2.1% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | -0.7% | — | — | |
| Q4 2010 | -0.7% | — | — | |
| Q3 2010 | +2.2% | — | — | |
| Q3 2009 | +2.2% | — | — | |
| Q2 2009 | +6.2% | — | — | |
| Q2 2010 | +6.2% | — | — | |
| Q4 2009 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro